Education
About Us
Working with TipRanks
Follow Us
Replicel (REPCF)
:REPCF
REPCF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $0.04
Previous CloseN/A
Volume18.85K
Average Volume (3M)0.00
Market Cap
$771.21K
Enterprise Value$6.57M
Total Cash (Recent Filing)$148.95K
Total Debt (Recent Filing)C$1.24M
Price to Earnings (P/E)0.6
Beta303.86
Next Earnings
Sep 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding70,003,020
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-0.54
Price to Sales (P/S)0.00
P/FCF Ratio-2.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
RepliCel Life Sciences News
PremiumCompany Announcements
RepliCel Life Sciences Finalizes Asset Sale and Announces Delisting Plans
PremiumCompany Announcements
RepliCel Life Sciences Reschedules Meeting and Board Update
PremiumCompany Announcements
RepliCel Life Sciences Urges Online Access for Shareholders
PremiumCompany Announcements
RepliCel Sells Assets and Licenses Patents for Shareholder GainPremiumCompany Announcements
RepliCel Secures Million Dollar CEO-Backed LoanPremiumCompany Announcements
RepliCel Proposes Asset Sale to Secure Future Royalties
PremiumCompany Announcements
RepliCel Plans Asset Sale and Delisting StrategyOptions Prices
Currently, No data available
---
Ownership Overview
REPCF FAQ
What was Replicel’s price range in the past 12 months?
Replicel lowest stock price was $0.01 and its highest was $0.04 in the past 12 months.
What is Replicel’s market cap?
Replicel’s market cap is $771.21K.
When is Replicel’s upcoming earnings report date?
Replicel’s upcoming earnings report date is Sep 01, 2025 which is in 62 days.
How were Replicel’s earnings last quarter?
Replicel released its earnings results on May 22, 2025. The company reported -$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.085.
Is Replicel overvalued?
According to Wall Street analysts Replicel’s price is currently Overvalued.
Does Replicel pay dividends?
Replicel does not currently pay dividends.
What is Replicel’s EPS estimate?
Replicel’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Replicel have?
Replicel has 70,003,020 shares outstanding.
What happened to Replicel’s price movement after its last earnings report?
Replicel reported an EPS of -$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Replicel?
Currently, no hedge funds are holding shares in REPCF
Company Description
Replicel
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.